SciSparc Receives Approval to Conduct Its Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome

SciSparc Ltd. announced the approval of the Israeli Ministry of Health to conduct its clinical trial titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.